Astellas may loss nearly $100 Million in a FDA delayed review
- The new coronavirus may kill cancer cells and achieve a permanent cure!
- Why did the Alzheimer’s drug candidate BACE1 inhibitor fail?
- LRTI Death: Research spanning 80 years confirms for the first time
- The decline of the global antibiotic market is threatening the development of new drugs
- World first: An mRNA vaccine that can 100% protect against deadly bacterial infections is available
- The first successful use of CAR-T cells to treat severe muscle inflammation
Astellas may loss nearly $100 Million in a FDA delayed review
- More than 1 million Chinese died after China quit “Zero-COVID policy”?
- Why is Vinyl chloride listed as a Class A “known human carcinogen” ?
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
Astellas may loss nearly $100 Million in a FDA delayed review.
On February 19, Astellas announced that the U.S. Food and Drug Administration (FDA) has notified the company that it will extend its original priority review for fezolinetant, a new drug for the treatment of moderate to severe vasomotor symptoms (VMS) caused by menopause.
Prescription Drug User Fee Act (PDUFA) target date. The FDA extended the PDUFA target date by three months to May 22, 2023 to allow more time to complete the review.
Fezolinetant is an oral, non-hormonal therapy indicated for the treatment of moderate to severe VMS in postmenopausal women.
The drug modulates neuronal activity in the thermoregulatory center of the brain (hypothalamus) by blocking the binding of neurokinin B (NKB) to kisspeptin/neurokinin B/dynorphin (KNDy) neurons, thereby reducing the Frequency and severity of moderate to severe VMS.
On June 23, 2022, Astellas submitted a new drug application (NDA) for fezolinetant to the FDA.
It is worth mentioning that Astellas used the Priority Review Voucher (PRV) when submitting the fezolinetant marketing application, which shortened the review time by four months. After the FDA accepted it, the approval decision date was February 22, 2023.
For priority review vouchers, Astellas registered an amortization of intangible assets worth 13.1 billion yen ($97 million) in the first quarter of fiscal 2022. Today, the advantage of shortened review periods provided by Priority Review Vouchers is almost gone.
The use of the Priority Review Voucher reflects Astellas’ confidence in the drug candidate, and the data from the Phase III BRIGHT SKY trial is the basis for Astellas’ submission of fezolinetant to the FDA, as well as its submission to Europe.
In this study, fezolinetant was superior to placebo in reducing the frequency and severity of moderate to severe vasomotor symptoms, including hot flashes and night sweats.
Astellas identified fezolinetant as the main driver of the company’s sales growth. According to a report by Jefferies in March 2022, the market potential of fezolinetant is estimated to be as high as $2.3 billion.
Astellas acquired fezolinetant when it bought Ogeda in 2017, in a deal that cost 500 million euros ($550 million) upfront and had an additional 300 million euros in milestones.
Astellas may loss nearly $100 Million in a FDA delayed review
(source:internet, reference only)
Disclaimer of medicaltrend.org
